In beginning this overview, I want to acknowledge the fact that, even though I disagree with most of his conclusions, Bruce Ames has played an important role in further stimulating interest in cell proliferation in carcinogenesis. This meeting has provided a balanced discussion of the current state of knowledge in this field. It has also highlighted the complexities of cell proliferation, the need for further mechanistic studies, and the desirability of developing new methods that can be used to precisely quantitate the various parameters related to cell proliferation in the intact organism.
It seems likely that certain xenobiotics might produce their carcinogenic effects by disturbing specific steps in signal transduction pathways and the control of gene expression, thereby enhancing cell proliferation and clonal expansion. Thus, the potent tumor-promoting role of the phorbol esters and certain related compounds is due to their ability to bind to and activate protein kinase C (PKC), an enzyme that plays a key role in signal transduction (2, 4) . It will be of interest, therefore, to determine whether other nongenotoxic carcinogens (i.e., agents that do not directly damage DNA) might exert their effects through growth-factor receptors, phospholipases, G proteins, specific protein kinases, or transcription factors. Insights into these mechanisms would provide a more scientific basis for risk extrapolation between species and tissues and from high doses to low doses.
I want to emphasize that it appears that genotoxic agents, by inducing complex cellular responses to DNA damage, can also perturb cellular pathways of signal transduction and gene expression (2) . Thus, the effects of genotoxic agents on cell proliferation may not simply reflect nonspecific toxicity that occurs only at high doses of the agent. The phenomenon of inducible responses to DNA damage complicates risk extrapolation. The dose-response curve for the mutagenic effects of a given genotoxic agent may not be the same as the dose-response curve for the inducible effects produced by the same agent. The dose-response curve for carcinogenicity might, therefore, be a complex function of both types of effects. This curve could in turn be a function of numerous other variables (i.e., the target tissue, the species and age of the host, and parallel exposure to other agents). The mutational spectra in the p53 gene discussed at this meeting provide an exciting example of how mutations in the DNA of tumor cells might provide a fingerprint of the original causative agent and/or the original mutagenic event(s) involved in carcinogenesis. It will be of interest, therefore, to examine the mutational spectra of altered genes in tumors produced by nongenotoxic agents or by putative endogenous factors such as hormones or reactive forms of oxygen. These mutational spectra, when compared to those produced by known genotoxic agents, may provide clues to the underlying mechanisms.
At this meeting, several investigators discussed recent exciting findings on the factors that control the cell cycle and of check points that monitor the fidelity of each phase of the cell cycle. It seems likely that certain xenobiotic agents might enhance the carcinogenic process by affecting specific cyclins, the cdk protein kinases activated by these cyclins, or various protein kinases and protein phosphatases that also regulate these events. Furthermore, mutations in the related genes during the course of multistage carcinogenesis could abrogate normal check-point control mechanisms or influence the fidelity of DNA and chromosome replication, thus contributing to genomic instability. In this regard, it was of interest to learn that mutations in the p53 gene appear to abrogate a check-point related to DNA damage. Our laboratory recently found that a cyclin D gene, Prad 1, is amplified and overexpressed in about 25% of human esophageal cancers (5) . Abnormalities in this gene have also been seen in other types of human tumors (5, 6) . Thus the cyclin-cdk kinase system may represent an important set of cellular targets in multistage carcinogenesis.
Several speakers discussed interesting theoretical models of multistage carcinogenesis. My own view is that such models are highly useful in the design of new experiments. Since, however, each of these models makes several important assumptions, I believe that at the present time none of these models can be used to do quantitative risk assessment with confidence or precision. A major challenge for future research is to develop experimental methods for identifying and quantitating each of the individual steps in the multistage process so that risk assessment calculations can be done with greater confidence.
In conclusion, I want to list what I think are certain key questions and new frontiers in the field of environmental carcinogenesis. The first is that we need much more basic research on the cellular and molecular mechanisms that control cell proliferation, the cell cycle, and cell death. Closely related to these subjects is the need to expand our knowledge on mechanisms of signal transduction and the control of gene expression. Second, I would encourage intensive research on the possibility that certain xenobiotics exert their carcinogenic or other toxic effects on cells not by damaging DNA but by targeting specific cellular molecules involved in signal transduction, gene expression, and cell cycle control. Third, we need to develop convenient biomarkers that can be used to score for perturbations in the latter events, in cells in culture and in rodents that are exposed to putative carcinogens. It is hoped that some of these biomarkers can be used in humans as an extension of current molecular epidemiology studies because at the present time these studies are restricted mainly to studying genotoxic-type events. Fourth, we need to expand our research into the roles of dietary and hormonal factors in human cancer causation. It is possible that these factors act through both genotoxic and nongenotoxic mechanisms. In recent studies (4), we have obtained evidence that a high-fat diet might enhance colon carcinogenesis by leading to the formation in the lumen of the colon diacyglycerol, an activator of PKC. Other mechanisms should also be investigated, using both experimental models and human studies. Finally, the emerging interest in intervention approaches, including dietary modifications and chemoprevention, holds great promise in terms of cancer prevention (4) . These approaches should also help validate (or invalidate) some of the predictions made from experimental and epidemiologic studies, thus improving the science of risk assessment.
On behalf of all the conference participants, I want to thank the organizers and sponsors for providing an informative and stimulating conference on a fundamental area of biology that is highly relevant to the field of environmental health science. I am certain that the discussions we have had will catalyze advances in this important field of public health.
